Arena Pharmaceuticals, Inc.  

(Public, NASDAQ:ARNA)   Watch this stock  
Find more results for arna
1.75
+0.13 (8.02%)
After Hours: 1.75 0.00 (0.00%)
May 27, 4:25PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.62 - 1.76
52 week 1.30 - 5.12
Open 1.62
Vol / Avg. 2.39M/1.79M
Mkt cap 433.35M
P/E     -
Div/yield     -
EPS -0.43
Shares 243.04M
Beta -0.54
Inst. own 53%
Aug 3, 2016
Q2 2016 Arena Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 13, 2016
Arena Pharmaceuticals Inc Annual Shareholders Meeting - 12:00PM EDT - Add to calendar
Jun 10, 2016
Arena Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 12:00PM EDT - Add to calendar
May 9, 2016
Q1 2016 Arena Pharmaceuticals Inc Earnings Call
May 9, 2016
Q1 2016 Arena Pharmaceuticals Inc Earnings Release
Feb 29, 2016
Q4 2015 Arena Pharmaceuticals Inc Earnings Call
Feb 29, 2016
Q4 2015 Arena Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -218.83% -281.74%
Operating margin -194.93% -269.26%
EBITD margin - -232.70%
Return on average assets -34.70% -40.50%
Return on average equity -189.74% -214.06%
Employees 228 -
CDP Score - -

Address

6154 Nancy Ridge Dr
SAN DIEGO, CA 92121-3223
United States - Map
+1-858-4537200 (Phone)
+1-858-4537210 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that target G protein-coupled receptors (GPCRs). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management, and is being commercialized under the brand name, BELVIQ. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. APD334 is an orally available modulator of the sphingosine 1-phosphate subtype 1 (S1P1) receptor intended for the treatment of multiple sclerosis, psoriasis, inflammatory bowel diseases and rheumatoid arthritis. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases and an undisclosed orphan GPCR for central nervous system indication(s).

Officers and directors

Harry F. Hixson Jr., Ph.D. Director
Age: 77
Bio & Compensation  - Reuters
Dominic P. Behan Ph.D. Executive Vice President, Chief Scientific Officer, Director
Age: 51
Bio & Compensation  - Reuters
Steven W. Spector J.D. Executive Vice President, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
Craig M. Audet Ph.D. Senior Vice President - Operations and Head of Global Regulatory Affairs
Age: 51
Bio & Compensation  - Reuters
William R. Shanahan Jr., M.D., J.D. Senior Vice President, Chief Medical Officer
Age: 66
Bio & Compensation  - Reuters
Jennifer Kathleen Bielasz Vice President - Accounting, Controller, Principal Accounting Officer
Age: 52
Bio & Compensation  - Reuters
Christine Anna White M.D. Lead Independent Director
Age: 63
Bio & Compensation  - Reuters
Donald D. Belcher Independent Director
Age: 76
Bio & Compensation  - Reuters
Scott H. Bice Independent Director
Age: 68
Bio & Compensation  - Reuters
Tina Susan Nova Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters